Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
EJNMMI Reports|July 27, 2025
First-in-human experience of radiopharmaceutical therapy with [177Lu]Lu-DOTATATE in patients with advanced multiple myelomaWendy Delbart, Marie Vercruyssen, Rachele Danieli, et al.
EJNMMI Physics|June 2, 2026
Quantitative accuracy of 177Lu SPECT/CT imaging using ring-shaped CZT versus dual-head NaI systemsRachele Danieli, Clémentine Marin, Anna-Lena Theisen, et al.
Journal of Personalized Medicine|February 25, 2022
Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical AspectsRachele Danieli, Alessia Milano, Salvatore Gallo, et al.
EJNMMI Physics|October 18, 2023
Quantitative 177Lu SPECT/CT imaging for personalized dosimetry using a ring-shaped CZT-based cameraRachele Danieli, Martina Stella, Julian Leube, et al.
EJNMMI Physics|May 8, 2026
Multicenter comparison of radionuclide calibrators and SPECT/CT protocols for quantitative 177Lu imaging in clinical practiceWies Claeys, Kristof Baete, Laurence Beels, et al.
EJNMMI Research|November 18, 2024
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN studyRachele Danieli, Magdalena Mileva, Gwennaëlle Marin, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2025
[177Lu]Lu-PSMA SPECT/CT for early response assessment using quantitative RECIP 1.0Mutaz Kassas, Louise Devriendt, Martin Manley, et al.
Medical Physics|September 15, 2023
Technical note: Impact of dose voxel kernel (DVK) values on dosimetry estimates in 177 Lu and 90 Y radiopharmaceutical therapy (RPT) applicationsRachele Danieli, Daniele Pistone, Jonathan Tranel, et al.
Clinical Nuclear Medicine|June 24, 2024
177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN StudyMagdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 2, 2024
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN StudyMagdalena Mileva, Gwennaëlle Marin, Hugo Levillain, et al.
Pageof 1